E-selectin在脑卒中发病中的作用及机制研究血管紧张素受体拮抗剂预防脑卒中的系统评价
|
摘要
目的:高血压发病率高,在中国成人高达18.8 %,目前我国大约有2亿高血压病人。脑卒中是高血压病最重要的并发症,近年来脑卒中发生率呈持续上升趋势,且日趋年轻化。脑卒中一旦发生,后果严重,病人非死即残,要使幸存者恢复功能,耗时费力,因此,预防和治疗脑卒中已经成为科学研究迫切需要解决的问题。血压水平是一个非常重要的心脑血管危险因素和预测因子,血压愈高,脑卒中的危险性就愈大,且80 %的脑卒中和52 %的脑梗死因高血压而引发,降低血压可以显著预防脑卒中的发生,但降压治疗并不是唯一的预防策略,并且脑卒中发生的病理生理机制复杂,有必要进行进一步的深入研究,找出除了血压以外的其他关键因子或预防措施,针对这些因子或措施进行干预,作为防治脑卒中的新靶点。
近年来,炎症及其潜在治疗靶点成为医学研究的热点。适度的炎症反应有益于宿主抵抗不良因素的侵袭和促进组织修复。但另一方面,短时间内大量的细胞因子的释放及炎症级联反应又可造成严重的病理损伤。几乎在每种心血管疾病的发生和发展过程中,炎症反应均起了一定的作用。目前,动脉粥样硬化已被公认为是一种特异性的炎症反应。脑血管疾病是以血管病变为起始的疾病,与炎症也有着密切的联系。炎症反应参与了缺血性脑卒中的发病及损伤过程。小血管炎症反应是脑缺血后脑损伤级联反应当中的重要一环。脑缺血损伤级联反应中,大量细胞毒性成分诱导自由基和其他介质导致细胞因子和致炎酶原产生炎症反应,细胞因子上调内皮细胞受体,吸引白细胞并诱导他们迁移至受损脑组织。许多报道证实,缺血性脑损害区域内出现白细胞(以中性粒细胞为主)的聚集、浸润,从而加重脑损伤的过程,这一现象受到人们越来越多的关注。而白细胞的聚集、浸润与细胞黏附分子的参与密切相关,其中E-选择素(E-selectin)的作用尤为重要。E-selectin是细胞黏附分子选择素家族的一员,仅表达于活化的血管内皮细胞上。其靶细胞主要是多形核中性粒细胞、单核细胞和淋巴细胞,主要介导血管内皮细胞与淋巴细胞、中性粒细胞及血小板之间的黏附。E-selectin介导的黏附作用既不依赖于白细胞的活化,也不需要白细胞整合素的参与。内皮细胞上的E-selectin可锚定白细胞,有助于白细胞稳定地黏附于内皮细胞,继而迁移至血管外组织。最近的一项临床研究显示,颅内动脉硬化发展为脑卒中与炎症反应密切相关,而血清E-selectin等炎症因子水平可以作为颅内动脉硬化发展为脑卒中的预测因子。另有研究发现,急性脑缺血患者可溶性E-selectin在脑梗死组最高,可逆性脑缺血发作者稍低,短暂性脑缺血发作者最低,说明可溶性E-selectin水平与脑卒中严重程度有关。提示了E-selectin的拮抗剂/活性调节剂治疗急性脑缺血的可能性。
由于脑卒中的发病机制复杂,其预防和治疗均有待于深入研究。E-selectin是体内一种重要的细胞黏附因子,但E-selectin是否参与了缺血性脑卒中的发病及损伤过程?E-selectin参与脑卒中发病及损伤的确切机制是什么?目前尚不甚清楚。因此,本课题主要针对这两个问题进行研究,以期发现E-selectin的潜在治疗学意义,为脑卒中的防治研究工作提供新的思路。
方法:实验一:利用自发性高血压大鼠(SHR)和脑卒中倾向的自发性高血压大鼠(SHR-SP),比较正常饲养及盐负荷状态下这两种动物血清及脑组织中E-selectin水平的差异。实验二:取C57小鼠和E-selectin基因敲除(Es-/-)小鼠,电凝大脑中动脉(MCA),比较两种动物的脑梗死面积和神经学评分是否有差异。实验三:取C57小鼠和Es-/-小鼠,电凝MCA,应用western blot方法测定两种动物脑组织髓过氧化物酶(MPO)的含量,考察E-selectin对脑缺血后中性粒细胞的浸润是否有影响。实验四:考察E-selectin对脑缺血后炎症反应的影响。比较C57小鼠和Es-/-小鼠脑缺血后脑组织炎症因子IL-6、IL-1β和TNF-α的水平是否有差异。实验五:考察E-selectin对缺血后脑组织细胞凋亡的影响。TUNEL法测定缺血后脑组织的细胞凋亡情况。实验六:电镜检查E-selectin对缺血后脑组织微血管内皮细胞、神经元等细胞形态、超微结构的变化是否有影响。
结果:(1)正常饲料组SHR-SP的脑组织和血清中E-selectin的含量均较SHR有升高趋势,但无统计学差异;SHR和SHR-SP喂饲4 %的高盐饲料1个月后,SHR-SP血清和脑组织中E-selectin的含量均显著高于SHR。提示E-selectin有可能参与了SHR-SP自发性脑卒中的发生过程。(2) MCA栓塞后,C57组动物的神经学评分和脑梗死面积均明显低于Es-/-组小鼠,表明E-selectin敲除对脑卒中有显著的保护作用。(3) Western blot结果显示,Es-/-组小鼠脑组织MPO的含量明显低于C57组小鼠,表明E-selectin敲除可以明显减轻缺血后脑组织中性粒细胞的浸润。(4)脑缺血后,脑组织IL-6和TNF-α水平在Es-/-组小鼠和C57组小鼠之间没有明显差异,Es-/-组小鼠的IL-1β水平明显低于C57组小鼠。(5) TUNEL结果显示,Es-/-组小鼠脑梗死区细胞凋亡程度比C57组小鼠明显减轻;表明抑制E-selectin表达可以减轻脑缺血诱导的细胞凋亡。(6)电镜检查结果显示,脑缺血后C57组小鼠的细胞损伤较Es-/-组小鼠严重,C57组小鼠可见核固缩、内皮细胞膜厚薄不均等,而Es-/-组小鼠细胞形态基本正常。
结论:(1) E-selectin参与了脑卒中的发生发展过程,抑制E-selectin表达可以减轻急性缺血性脑损伤程度。(2) E-selectin表达受抑制后,脑组织中性粒细胞的浸润明显减轻;脑组织IL-1β的含量显著降低。(3)抑制E-selectin表达可以减轻脑缺血诱导的细胞凋亡及损伤。
目的:血管紧张素转换酶抑制剂(angiotensin converting enzyme inhibitors, ACEI)和血管紧张素受体拮抗药(angiotensin receptor blockers, ARB)已经被广泛应用于心脑血管意外的高危人群。目前,ACEI预防脑卒中的有效性得到一致肯定。本研究通过对以往发表的有关ARB治疗心血管意外高危人群的所有随机对照临床试验进行系统评价,以明确ARB预防脑卒中的有效性。
方法:电子检索PubMed、EMBASE和Cochrane图书馆为主要来源,搜索至2008年公开发表的ARB干预心脑血管意外高危人群的随机对照临床试验。根据选择标准选择合适的文献,选择标准为比较ARB与安慰剂、ACEI、钙离子拮抗剂预防脑卒中的随机对照临床试验,并对纳入的相关文献进行质量评估和相关数据提取。摘录数据包括患者特征、干预措施、试验质量、治疗终点。主要疗效评判指标为脑卒中。采用RevMan 5.0系统评价软件的随机效应模型,对比较ARB与安慰剂、ACEI、钙离子拮抗剂进行合并,计算效应量,并进行敏感性分析和发表偏倚的评估。
结果:总计20项随机对照临床试验纳入荟萃分析,收录108286例患者。安慰剂对照临床试验11项,纳入患者44971例,荟萃分析显示,与安慰剂相比,ARB可以显著降低脑卒中的发生率,合并比值比为0.91 (95 % CI 0.84, 0.98)。总计有6项临床试验(36537例心脑血管意外高危患者)比较了ARB与ACEI预防脑卒中的有效性,荟萃分析的合并比值比为0.93 (95 % CI 0.84, 1.03),两组之间的差异不具有统计学意义。总计有4项临床试验(22446例)比较了ARB与钙离子拮抗剂预防脑卒中的有效性,两组之间的差异同样不具有统计学意义,合并比值比为1.16 (95 % CI 0.91, 1.48)。
结论:与安慰剂相比,ARB可以显著降低脑卒中发生率;而与ACEI、钙离子拮抗剂相比,ARB具有相近的脑卒中发生率,因此,相对于高血压、糖尿病、心力衰竭、脑卒中等心脑血管意外高危人群来说,ARB是预防脑卒中的恰当选择。
Objectives: Hypertension is one of the most common cardiovascular diseases with high incidence (18.8 %) and mortality resulting from stroke, myocardial infarction, congestive heart failure and end-stage renal disease in China. As the major complication of hypertension, stroke makes a considerable contribution to morbidity and mortality especially for young people. It constitutes a formidable burden of disability and misery for the patients and their relatives and the wider community. Many stroke survivors become dependent, and require lifelong assistance. Given the disease burden of stroke, prevention is an important public health concern to curb the stroke pandemicly. Blood pressure level is one of the most consistent and powerful predictor of stroke. Hypertension accounts for 80 % of stroke risk and 52 % of cerebral infarction attack. So blood pressure control has been conclusively shown to prevent stroke. However, blood pressure level is not the unique determinant for stroke. Here we propose other important determinants for stroke.
Accumulating evidence suggests that inflammation plays important roles in the development of acute cerebrovascular disease. Inflammation has been implicated as a secondary mechanism underlying neuronal injury induced by ischemia. A variety of experimental models, including thromboembolic stroke, focal and global ischemia, have been used to evaluate contributions of inflammation to neuronal damage. Endothelial dysfunction represents an early phase of inflammation. Adhesion molecules are involved in leukocyte rolling, firm adhesion and transmigration across endothelial cells, and play an important role in inflammatory disorders. The vasculature endothelium promotes inflammation through upregulation of adhesion molecules that bind to circulating leukocytes and facilitate migration of leukocytes into the central nervous system (CNS). Once being in the CNS, leukocytes produce cytotoxic molecules that promote cell death. During this process, E-selectin is needed to play as an initiator. E-selectin belongs to the selectin family of adhesion molecules and is observed only on activated endothelium. It can serve as an activated endothelial marker. A clinical study indicated that inflammatory factors including E-selectin are involved in the development from intracranial arteriosclerosis to stroke, and serum E-selectin can serve as a predictor. It was found in another study that soluble E-selectin level is highest in patients with cerebral infarction, slight lower in patients with reversible ischemic attack, and lowest in patients with transient ischemic attack, indicating that E-selectin is related to the severity of stroke. These results suggest the promise for the therapy of stroke by using antagonists of E-selectin.
As mentioned above, E-selectin is an important adhesion molecule and involved in the onset and pathologic lesion of stroke. But what are the exact mechanisms for the involvement of E-selectin in stroke? Whether E-selectin can be the target for stroke prevention and treatment? In this study, we mainly focussed on these two questions. The effect of E-selectin on stroke and the possible mechanisms involved were investigated. It might develop a new way to find the effective factors involved in the prevention and treatment of stroke. Recent results obtained in clinical trials for asthma and psoriasis show that, although very challenging, the development of E-selectin antagonists holds concrete promise for the therapy of inflammatory diseases.
Methods: E-selectin levels of brain and serum were compared between spontaneously hypertensive rats (SHRs) and stroke-prone spontaneously hypertensive rats (SHR-SPs) after a normal diet or a high salt diet (4 % NaCl) was given for 1 month. To further verify the role of E-selectin on stroke, animal model of acute ischemic stroke by electric coagulation of middle cerebral artery were made in E-selectin knockout (Es-/-) mice and C57 mice. The infarct area and hemisphere areas of each section (both sides) were traced and quantified by an image analysis system. Infarct area and neurological score were compared between these two animals. The possible mechanisms of the involvement of E-selectin in stroke were studied in Es-/- mice and C57 mice. The effect of E-selectin on neutrophil infiltration was examined by detecting MPO level in brain using western blot method. To examine the effect of E-selectin on inflammation, levels of IL-6, IL-1βand TNF-αin brain were detected using ELISA method 8 h after MCA occlusion. In situ detection of apoptotic cell by the TUNEL method was performed 24 h after MCA occlusion.
Results: The brain and serum E-selectin levels were higher in SHR-SPs than in SHRs (P<0.05) after salt intake, suggesting that E-selectin might be one of the key processes in the pathogenesis of stroke. The ratio of the infarct area and hemisphere areas and neurological score were significantly decreased in Es-/- mice than in C57 mice. MPO level was much lower in Es-/- mice than in C57 mice after MCA occlusion, suggesting neutrophil infiltration was significantly relieved by inhibiting E-selectin expression. IL-1βlevel was significantly higher in C57 mice than in Es-/- mice, but there was no difference in IL-6 and TNF-αlevels between these two animals. Cell apoptosis was significantly lessened in Es-/- mice than in C57 mice.
Conclusions: The present study provides evidence that E-selectin is involved in the pathogenesis of stroke. Inhibiting expression of E-selectin presents protective effect on ischemic lesions. This protective effect results from the inhibition of neutrophil infiltration and the reduction of IL-1βlevel, and then relieving the cell apoptosis induced by ischemia.
Objectives: Angiotensin converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) are widely used in patients who are at high risk of cardiovascular events. A consensus has emerged that ACEI can reduce the risk of stroke. This research of overviews of randomized trials was established to investigate the effects of ARB on the prevention of stroke in patients at high risk for cardio-cerebrovascular events.
Methods: Electronic databases were searched up to December, 2008, for randomized clinical trials concerning ARB treatments in patients at high risk for cardio-cerebrovascular events. A selection criterion was established to select and evaluate the appropriate literature by comparing randomized trials of ARB with placebo, ACEI, and calcium antagonists. Data were extracted for patients’characteristics, interventions, quality of trials, and rates of stroke. The efficacy measures were the odds ratios of strokes. We did separate overviews of trials comparing ARB with placebo, with ACEI, and with calcium antagonists. The pooled effects were calculated using the random effects model by RevMan 5.0.
Results: Twenty randomized clinical trials with 108286 patients were included in the analysis. The overview of placebo-controlled trials (11 trials, 44971 patients) revealed ARBs was associated with a significant reduction in the risk of stroke, with a pooled odds ratio of 0.91 (0.84 to 0.98). In the overview of trials comparing ARB with ACEI (6 trials, 36537 patients), there were no significant reduced risks of stroke with ARB (odds ratio 0.93, 0.84 to 1.03). In the overviews comparing ARB with calcium antagonists (4 trials, 22446 patients), no significant difference was found, with a pooled ratio of 1.16 (0.91 to 1.48).
Conclusion: Significant benefits of ARB on the risk of stroke are demonstrated by comparing to the overviews of placebo-controlled trials. There was no evidence of differences when comparing ARB with ACEI, and with calcium antagonists. Therefore, ARB should be regarded as suitable treatments for preventing stroke in patients who are at high risk of cardiovascular events.
近年来,炎症及其潜在治疗靶点成为医学研究的热点。适度的炎症反应有益于宿主抵抗不良因素的侵袭和促进组织修复。但另一方面,短时间内大量的细胞因子的释放及炎症级联反应又可造成严重的病理损伤。几乎在每种心血管疾病的发生和发展过程中,炎症反应均起了一定的作用。目前,动脉粥样硬化已被公认为是一种特异性的炎症反应。脑血管疾病是以血管病变为起始的疾病,与炎症也有着密切的联系。炎症反应参与了缺血性脑卒中的发病及损伤过程。小血管炎症反应是脑缺血后脑损伤级联反应当中的重要一环。脑缺血损伤级联反应中,大量细胞毒性成分诱导自由基和其他介质导致细胞因子和致炎酶原产生炎症反应,细胞因子上调内皮细胞受体,吸引白细胞并诱导他们迁移至受损脑组织。许多报道证实,缺血性脑损害区域内出现白细胞(以中性粒细胞为主)的聚集、浸润,从而加重脑损伤的过程,这一现象受到人们越来越多的关注。而白细胞的聚集、浸润与细胞黏附分子的参与密切相关,其中E-选择素(E-selectin)的作用尤为重要。E-selectin是细胞黏附分子选择素家族的一员,仅表达于活化的血管内皮细胞上。其靶细胞主要是多形核中性粒细胞、单核细胞和淋巴细胞,主要介导血管内皮细胞与淋巴细胞、中性粒细胞及血小板之间的黏附。E-selectin介导的黏附作用既不依赖于白细胞的活化,也不需要白细胞整合素的参与。内皮细胞上的E-selectin可锚定白细胞,有助于白细胞稳定地黏附于内皮细胞,继而迁移至血管外组织。最近的一项临床研究显示,颅内动脉硬化发展为脑卒中与炎症反应密切相关,而血清E-selectin等炎症因子水平可以作为颅内动脉硬化发展为脑卒中的预测因子。另有研究发现,急性脑缺血患者可溶性E-selectin在脑梗死组最高,可逆性脑缺血发作者稍低,短暂性脑缺血发作者最低,说明可溶性E-selectin水平与脑卒中严重程度有关。提示了E-selectin的拮抗剂/活性调节剂治疗急性脑缺血的可能性。
由于脑卒中的发病机制复杂,其预防和治疗均有待于深入研究。E-selectin是体内一种重要的细胞黏附因子,但E-selectin是否参与了缺血性脑卒中的发病及损伤过程?E-selectin参与脑卒中发病及损伤的确切机制是什么?目前尚不甚清楚。因此,本课题主要针对这两个问题进行研究,以期发现E-selectin的潜在治疗学意义,为脑卒中的防治研究工作提供新的思路。
方法:实验一:利用自发性高血压大鼠(SHR)和脑卒中倾向的自发性高血压大鼠(SHR-SP),比较正常饲养及盐负荷状态下这两种动物血清及脑组织中E-selectin水平的差异。实验二:取C57小鼠和E-selectin基因敲除(Es-/-)小鼠,电凝大脑中动脉(MCA),比较两种动物的脑梗死面积和神经学评分是否有差异。实验三:取C57小鼠和Es-/-小鼠,电凝MCA,应用western blot方法测定两种动物脑组织髓过氧化物酶(MPO)的含量,考察E-selectin对脑缺血后中性粒细胞的浸润是否有影响。实验四:考察E-selectin对脑缺血后炎症反应的影响。比较C57小鼠和Es-/-小鼠脑缺血后脑组织炎症因子IL-6、IL-1β和TNF-α的水平是否有差异。实验五:考察E-selectin对缺血后脑组织细胞凋亡的影响。TUNEL法测定缺血后脑组织的细胞凋亡情况。实验六:电镜检查E-selectin对缺血后脑组织微血管内皮细胞、神经元等细胞形态、超微结构的变化是否有影响。
结果:(1)正常饲料组SHR-SP的脑组织和血清中E-selectin的含量均较SHR有升高趋势,但无统计学差异;SHR和SHR-SP喂饲4 %的高盐饲料1个月后,SHR-SP血清和脑组织中E-selectin的含量均显著高于SHR。提示E-selectin有可能参与了SHR-SP自发性脑卒中的发生过程。(2) MCA栓塞后,C57组动物的神经学评分和脑梗死面积均明显低于Es-/-组小鼠,表明E-selectin敲除对脑卒中有显著的保护作用。(3) Western blot结果显示,Es-/-组小鼠脑组织MPO的含量明显低于C57组小鼠,表明E-selectin敲除可以明显减轻缺血后脑组织中性粒细胞的浸润。(4)脑缺血后,脑组织IL-6和TNF-α水平在Es-/-组小鼠和C57组小鼠之间没有明显差异,Es-/-组小鼠的IL-1β水平明显低于C57组小鼠。(5) TUNEL结果显示,Es-/-组小鼠脑梗死区细胞凋亡程度比C57组小鼠明显减轻;表明抑制E-selectin表达可以减轻脑缺血诱导的细胞凋亡。(6)电镜检查结果显示,脑缺血后C57组小鼠的细胞损伤较Es-/-组小鼠严重,C57组小鼠可见核固缩、内皮细胞膜厚薄不均等,而Es-/-组小鼠细胞形态基本正常。
结论:(1) E-selectin参与了脑卒中的发生发展过程,抑制E-selectin表达可以减轻急性缺血性脑损伤程度。(2) E-selectin表达受抑制后,脑组织中性粒细胞的浸润明显减轻;脑组织IL-1β的含量显著降低。(3)抑制E-selectin表达可以减轻脑缺血诱导的细胞凋亡及损伤。
目的:血管紧张素转换酶抑制剂(angiotensin converting enzyme inhibitors, ACEI)和血管紧张素受体拮抗药(angiotensin receptor blockers, ARB)已经被广泛应用于心脑血管意外的高危人群。目前,ACEI预防脑卒中的有效性得到一致肯定。本研究通过对以往发表的有关ARB治疗心血管意外高危人群的所有随机对照临床试验进行系统评价,以明确ARB预防脑卒中的有效性。
方法:电子检索PubMed、EMBASE和Cochrane图书馆为主要来源,搜索至2008年公开发表的ARB干预心脑血管意外高危人群的随机对照临床试验。根据选择标准选择合适的文献,选择标准为比较ARB与安慰剂、ACEI、钙离子拮抗剂预防脑卒中的随机对照临床试验,并对纳入的相关文献进行质量评估和相关数据提取。摘录数据包括患者特征、干预措施、试验质量、治疗终点。主要疗效评判指标为脑卒中。采用RevMan 5.0系统评价软件的随机效应模型,对比较ARB与安慰剂、ACEI、钙离子拮抗剂进行合并,计算效应量,并进行敏感性分析和发表偏倚的评估。
结果:总计20项随机对照临床试验纳入荟萃分析,收录108286例患者。安慰剂对照临床试验11项,纳入患者44971例,荟萃分析显示,与安慰剂相比,ARB可以显著降低脑卒中的发生率,合并比值比为0.91 (95 % CI 0.84, 0.98)。总计有6项临床试验(36537例心脑血管意外高危患者)比较了ARB与ACEI预防脑卒中的有效性,荟萃分析的合并比值比为0.93 (95 % CI 0.84, 1.03),两组之间的差异不具有统计学意义。总计有4项临床试验(22446例)比较了ARB与钙离子拮抗剂预防脑卒中的有效性,两组之间的差异同样不具有统计学意义,合并比值比为1.16 (95 % CI 0.91, 1.48)。
结论:与安慰剂相比,ARB可以显著降低脑卒中发生率;而与ACEI、钙离子拮抗剂相比,ARB具有相近的脑卒中发生率,因此,相对于高血压、糖尿病、心力衰竭、脑卒中等心脑血管意外高危人群来说,ARB是预防脑卒中的恰当选择。
Objectives: Hypertension is one of the most common cardiovascular diseases with high incidence (18.8 %) and mortality resulting from stroke, myocardial infarction, congestive heart failure and end-stage renal disease in China. As the major complication of hypertension, stroke makes a considerable contribution to morbidity and mortality especially for young people. It constitutes a formidable burden of disability and misery for the patients and their relatives and the wider community. Many stroke survivors become dependent, and require lifelong assistance. Given the disease burden of stroke, prevention is an important public health concern to curb the stroke pandemicly. Blood pressure level is one of the most consistent and powerful predictor of stroke. Hypertension accounts for 80 % of stroke risk and 52 % of cerebral infarction attack. So blood pressure control has been conclusively shown to prevent stroke. However, blood pressure level is not the unique determinant for stroke. Here we propose other important determinants for stroke.
Accumulating evidence suggests that inflammation plays important roles in the development of acute cerebrovascular disease. Inflammation has been implicated as a secondary mechanism underlying neuronal injury induced by ischemia. A variety of experimental models, including thromboembolic stroke, focal and global ischemia, have been used to evaluate contributions of inflammation to neuronal damage. Endothelial dysfunction represents an early phase of inflammation. Adhesion molecules are involved in leukocyte rolling, firm adhesion and transmigration across endothelial cells, and play an important role in inflammatory disorders. The vasculature endothelium promotes inflammation through upregulation of adhesion molecules that bind to circulating leukocytes and facilitate migration of leukocytes into the central nervous system (CNS). Once being in the CNS, leukocytes produce cytotoxic molecules that promote cell death. During this process, E-selectin is needed to play as an initiator. E-selectin belongs to the selectin family of adhesion molecules and is observed only on activated endothelium. It can serve as an activated endothelial marker. A clinical study indicated that inflammatory factors including E-selectin are involved in the development from intracranial arteriosclerosis to stroke, and serum E-selectin can serve as a predictor. It was found in another study that soluble E-selectin level is highest in patients with cerebral infarction, slight lower in patients with reversible ischemic attack, and lowest in patients with transient ischemic attack, indicating that E-selectin is related to the severity of stroke. These results suggest the promise for the therapy of stroke by using antagonists of E-selectin.
As mentioned above, E-selectin is an important adhesion molecule and involved in the onset and pathologic lesion of stroke. But what are the exact mechanisms for the involvement of E-selectin in stroke? Whether E-selectin can be the target for stroke prevention and treatment? In this study, we mainly focussed on these two questions. The effect of E-selectin on stroke and the possible mechanisms involved were investigated. It might develop a new way to find the effective factors involved in the prevention and treatment of stroke. Recent results obtained in clinical trials for asthma and psoriasis show that, although very challenging, the development of E-selectin antagonists holds concrete promise for the therapy of inflammatory diseases.
Methods: E-selectin levels of brain and serum were compared between spontaneously hypertensive rats (SHRs) and stroke-prone spontaneously hypertensive rats (SHR-SPs) after a normal diet or a high salt diet (4 % NaCl) was given for 1 month. To further verify the role of E-selectin on stroke, animal model of acute ischemic stroke by electric coagulation of middle cerebral artery were made in E-selectin knockout (Es-/-) mice and C57 mice. The infarct area and hemisphere areas of each section (both sides) were traced and quantified by an image analysis system. Infarct area and neurological score were compared between these two animals. The possible mechanisms of the involvement of E-selectin in stroke were studied in Es-/- mice and C57 mice. The effect of E-selectin on neutrophil infiltration was examined by detecting MPO level in brain using western blot method. To examine the effect of E-selectin on inflammation, levels of IL-6, IL-1βand TNF-αin brain were detected using ELISA method 8 h after MCA occlusion. In situ detection of apoptotic cell by the TUNEL method was performed 24 h after MCA occlusion.
Results: The brain and serum E-selectin levels were higher in SHR-SPs than in SHRs (P<0.05) after salt intake, suggesting that E-selectin might be one of the key processes in the pathogenesis of stroke. The ratio of the infarct area and hemisphere areas and neurological score were significantly decreased in Es-/- mice than in C57 mice. MPO level was much lower in Es-/- mice than in C57 mice after MCA occlusion, suggesting neutrophil infiltration was significantly relieved by inhibiting E-selectin expression. IL-1βlevel was significantly higher in C57 mice than in Es-/- mice, but there was no difference in IL-6 and TNF-αlevels between these two animals. Cell apoptosis was significantly lessened in Es-/- mice than in C57 mice.
Conclusions: The present study provides evidence that E-selectin is involved in the pathogenesis of stroke. Inhibiting expression of E-selectin presents protective effect on ischemic lesions. This protective effect results from the inhibition of neutrophil infiltration and the reduction of IL-1βlevel, and then relieving the cell apoptosis induced by ischemia.
Objectives: Angiotensin converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) are widely used in patients who are at high risk of cardiovascular events. A consensus has emerged that ACEI can reduce the risk of stroke. This research of overviews of randomized trials was established to investigate the effects of ARB on the prevention of stroke in patients at high risk for cardio-cerebrovascular events.
Methods: Electronic databases were searched up to December, 2008, for randomized clinical trials concerning ARB treatments in patients at high risk for cardio-cerebrovascular events. A selection criterion was established to select and evaluate the appropriate literature by comparing randomized trials of ARB with placebo, ACEI, and calcium antagonists. Data were extracted for patients’characteristics, interventions, quality of trials, and rates of stroke. The efficacy measures were the odds ratios of strokes. We did separate overviews of trials comparing ARB with placebo, with ACEI, and with calcium antagonists. The pooled effects were calculated using the random effects model by RevMan 5.0.
Results: Twenty randomized clinical trials with 108286 patients were included in the analysis. The overview of placebo-controlled trials (11 trials, 44971 patients) revealed ARBs was associated with a significant reduction in the risk of stroke, with a pooled odds ratio of 0.91 (0.84 to 0.98). In the overview of trials comparing ARB with ACEI (6 trials, 36537 patients), there were no significant reduced risks of stroke with ARB (odds ratio 0.93, 0.84 to 1.03). In the overviews comparing ARB with calcium antagonists (4 trials, 22446 patients), no significant difference was found, with a pooled ratio of 1.16 (0.91 to 1.48).
Conclusion: Significant benefits of ARB on the risk of stroke are demonstrated by comparing to the overviews of placebo-controlled trials. There was no evidence of differences when comparing ARB with ACEI, and with calcium antagonists. Therefore, ARB should be regarded as suitable treatments for preventing stroke in patients who are at high risk of cardiovascular events.
引文
[1] Franco V, Oparil S, Carretero OA. Hypertensive Therapy: PartⅠ. Circulation, 2004, 109(24): 2953-2958.
[2] Franco V, Oparil S, Carretero OA. Hypertensive Therapy: PartⅡ. Circulation, 2004, 109(25): 3081-3088.
[3]秦震.我国缺血性脑卒中防治研究中存在的问题及对策.中华医学, 2000,80(2):85-86.
[4] Arboix A, Morcillo C, Garcia-Eroles L, Oliveres M, Massons J, Targa C. Different vascular risk factor profiles in ischemic stroke subtypes: a study from the "Sagrat Cor Hospital of Barcelona Stroke Registry". Acta Neurol Scand, 2000, 102(4):264-270.
[5] Vilas AP, Veiga MZ, Santos ME, Abecasis P. Hemorrhagic stroke: experience of an internal medicine department. Rev Port Cardiol, 2001, 20(2):157-165.
[6] Wolf-Maier K, Cooper RS, Banegas JR, Giampaoli S, Hense HW, Joffres M, Kastarinen M, Poulter N, Primatesta P, Rodríguez-Artalejo F, Stegmayr B, Thamm M, Tuomilehto J, Vanuzzo D, Vescio F. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA, 2003, 289(18):2363-2369.
[7] Lusis AJ. Atherosclerosis. Nature, 2000, 407(6801):233-241.
[8] Libby P, Ridker PM, Maseri A. Inflammation and Atherosclerosis. Circulation, 2002, 105(9):1135-1143.
[9] Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med, 1999, 340(2):115-126.
[10] Mulvihill NT, Foley JB. Inflammation in acute coronary syndroms. Heart, 2002, 87(3):201-204.
[11] Kaartinen M, Penttila A, Kovanen PT. Accumulation of activated mast cells in the shoulder regions of human coronary atheroma, the predilection site of atheromatous rupture. Circulation, 1994, 90(4):1669-1678.
[12] Libby P. Changing concepts of atherogenesis. J Intern Med, 2000, 247(3):349-358.
[13] Bevilacqua MP, Stengelin S, Gimbrone MA Jr, Seed B. Endothelial leukocyte adhesion molecule 1: an inducible receptor for neutrophils related to complement regulatory proteins and lectins. Science, 1989, 243(4895):1160-1165.
[14] Essani NA, McGuire GM, Manning AM, Jaeschke H. Endotoxin-induced actiration of the nuclear transcription factor xB and expression of E-seleetin messenger RNA in hepatocytes, kupfer cells and endothelial cells in vivo. J Immtmol, 1996, 156(8): 2956-2963.
[15] Lawson JA, Burns AR, Farhood A, Lynn Bajt M, Collins RG, Smith CW, Jaeschke H.Pathophysiologie importance of E-and L-selectin for neutrophil-incoeed liver injurv during endotoxe miain mice. Hepatology, 2000, 32(5): 990-998.
[16] Kansas GS. Selectins and their ligands: current concepts and controversies. Blood, l996, 88(9): 3259-3287.
[17] Arenillas JF, Alvarez-Sabín J, Molina CA, Chacón P, Fernández-Cadenas I, Ribo M, Delgado P, Rubiera M, Penalba A, Rovira A, Montaner J. Progression of symptomatic intracranial large artery atherosclerosis is associated with a proinflammatory state and impaired fibrinolysis. Stroke, 2008, 39(5):1456-1463.
[18] Mizia-Stec K, Mandecki T, Zahorska-Markiewicz B, Janowska J, Szulc A, Jastrzebska-OkońK, Twardowski R. P-selectin and E-selectin in serum of patients with stroke. Atherosclerosis, 2002, 161(2): 189-193.
[19] Swanson RA, Morton MT, Tsao-Wu G, Savalos RA, Davidson C, Sharp FR. A semiautomated method for measuring brain infarct volume. J Cereb Blood Flow Metab, 1990, 10(2):290-293.
[20] Zhu W, Fan Y, Frenzel T, Gasmi M, Bartus RT, Young WL, Yang GY, Chen Y. Insulin growth factor-1 gene transfer enhances neurovascular remodeling and improves long-term stroke outcome in mice. Stroke, 2008, 39(4):1254-1261.
[21] Feeney DM, Gonzalez A, Law WA. Amphetamine, haloperidol, and experience interact to affect rate of recovery after motor cortex injury. Science, 1982,217(4562):855-857.
[22] Borlongan CV, Tajima Y, Trojanowski JQ, Lee VM, Sanberg PR. Transplantation of cryopreserved human embryonal carcinoma-derived neurons (NT2N cells) promotes functional recovery ischemic rats. Exp Neurol, 1998,149(2):310-321.
[23] Miao CY, Xie HH, Zhan LS, Su DF. Blood pressure variability is more important than blood pressure level in determination of end-organ damage in rats. J Hypertens, 2006, 24(6):1125-1135.
[24] Liu JG, Xu LP, Chu ZX, Miao CY, Su DF. Contribution of blood pressure variability to the effect of nitrendipine on end-organ damage in spontaneously hypertensive rats. J Hypertens, 2003, 21(10):1961-1967.
[25] Kunkel EJ, Ley K. Distinct phenotype of E-selectin-deficient mice.E-selectin is required for slow leukocyte rolling in vivo. Circ Res, 1996,79(6):1196-1204.
[26] Okamoto K, Yamori Y, Nagaoka A. Establishment of the stroke-prone spontaneously hypertensive rat. Circ Res, 1974,1(2):143-153.
[27] Zeng J, Zhang Y, Mo J, Su Z, Huang R. Two-kidney, two clip renovascular hypertensive rats can be used as stroke-prone rats. Stroke, 1998,29(8):1708-1714.
[28] Becker KJ. Targeting the central nervous system inflammatory response in ischemic stroke. CurtOpin Neurol, 2001;14(3):349-353.
[29] Jean WC, Spellman SR, Nussbaum ES, Low WC. Reperfusion after focal cerebral ischemia: the role of inflammation and the therapeutic horizon. Neurosurgery, 1998,43(6):1382-l396.
[30] Grady MS, Cody RF Jr, Maris DO, McCall TD, Seckin H, Sharar SR, Winn HR. P-selectin blockade following fluid percussion injury: behavioral and immuno-chemical sequelae. J Neurotrauma, 1999, 16(1):13-25.
[31] Clark RS, Schiding JK, Kaczorowski SL, Marion DW, Kochanek PM. Neutrophil accumulation after traumatic brain injury in rats: comparison of weight drop and controlled cortical impact models. J Neurotrauma, 1994,11(5):499-506.
[32] Schoettle RJ, Kochanek PM, Magargee MJ, Uhl MW, Nemoto EM. Early polymorphonuclear leukocyte accumulation correlates with the development of posttraumatic cerebral edema in rats. J Neurotrauma, 1990,7(4):207-217.
[33] Biagas KV, Uhl MW, Schiding JK, Nemoto EM, Kochanek PM. Assessment of posttraumatic polymorphonuclear leukocyte accumulation in rat brain using tissue myeloperoxidase assay and vinblastine treatment. J Neurotrauma, 1992, 9(4):363-371.
[34] Henson PM, Johnston RB Jr. Tissue injury in inflammation: oxidants, proteinases, and cationic proteins. J Clin Invest, 1987,79(3):669-674.
[35] Aly H, Khashaba MT, El-Ayouty M, El-Sayed O, Hasanein BM. IL-1beta, IL-6 and TNF-alpha and outcomes of neonatal hypoxic ischemic encephalopathy. Brain Dev, 2006,28(3):178-182.
[36] Rothwell NJ. Functions and mechanisms of interleukin-1 in the brain. Trends Pharmacol Sci, 1991, 12(11):430-436.
[37] Rothwell NJ, Luheshi G. Pharmacology of intedeukin-1 actions in the brain. Adv Phamaacol, 1994,25(6):1-20.
[38] Stoll G, Jander S, Schroeter M. Inflammation and glia responses in ischemic brain lesions. Prog Neurobiol, 1998,56(2):149-171.
[39] Sharma BK, Kumar K. Role of proinflammatory cytokines in cerebra ischemia. Metab Brain Dis, 1998,13(1):1-8.
[40] Yamasaki Y, Matsuura N, Shozuhara H, Onodera H, Itoyama Y, Kogure K. Interleukin-1 as a pathogenetic mediator of ischemic brain in rats. Stroke, 1995, 26(4): 676-681.
[41] Betz AL, Schiclke GP, Yang GY. Interleukin-1 in cerebral ischemia. Keio J Med, 1996, 45(3):230-238.
[42] Rothwell NJ, Relton JK. Involvement of interleukin-1 and lipocortin-1 in ischemic brain damage. Cerebrovasc Brain Metab Rev, 1993,5(3):178-198.
[43] Kuida K, Lippke JA, Ku G, Harding MW, Livingston DJ, Su MS, Flavell RA. Altered cytokine export and apoptosis in mice deficient in interleukin-1 beta converting enzyme. Science, 1995, 267(5206):2000-2003.
[44] Rothwell NJ. Sixteenth Gaddum Memorial Lecture December 1996. Neuroimmune interactions: the role of cytokines. Br J Pharmacol, 1997, 121(5):841- 847.
[45] Friedlander RM, Yuan J. ICE, neuronal apoptosis and neurodegeneration. Cell Death Diff, 1998, 5(10):823-831.
[1] Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet, 1997,349(9063):1436-1442.
[2] Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet, 2005,365(9455):217-223.
[3] Vongpatanasin W. Cardiovascular morbidity and mortality in high-risk populations: epidemiology and opportunities for risk reduction. J Clin Hypertens, 2007,9(Suppl 4):11-15.
[4] Wang JG, Staessen JA, Franklin SS, Fagard R, Gueyffier F. Systolic and diastolic blood pressure lowering as determinants of cardiovascular outcome. Hypertension, 2005,45(5):907-913.
[5] Elliott WJ. Therapeutic trials comparing angiotensin converting enzyme inhibitors and angiotensin II receptor blockers. Curr Hypertens Rep, 2000,2(4):402-411.
[6] Kleijnen J, Chalmers I. How to practice and teach evidence-based medicine: role of the Cochrane Collaboration. Acta Anaesthesiol Scand Suppl, 1997,111(2):231-233.
[7] Teo KK, Burton JR, Buller CE, Plante S, Catellier D, Tymchak W, Dzavik V, Taylor D, Yokoyama S, Montague TJ. Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: The Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT). Circulation, 2000,102(15):1748-1754.
[8] Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med, 2000,342(3):145-153.
[9] PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet, 2001,358(9287):1033-1041.
[10] Bosch J, Yusuf S, Pogue J, Sleight P, Lonn E, Rangoonwala B, Davies R, Ostergren J, Probstfield J; HOPE Investigators. Heart outcomes prevention evaluation. Use of ramipril in preventing stroke: double blind randomised trial. BMJ, 2002,324(7339):699-702.
[11] Neal B, MacMahon S, Chapman N; Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet, 2000,356(9246):1955-64.
[12] Carr AA, Prisant LM. Losartan: first of a new class of angiotensin antagonists for the management of hypertension. J Clin Pharmacol, 1996,36(1):3-12.
[13] Elliott WJ. Therapeutic trials comparing angiotensin converting enzyme inhibitors and angiotensin II receptor blockers. Curr Hypertens Rep, 2000, 2(4):402-411.
[14] Yusuf S, Diener HC, Sacco RL, Cotton D, Ounpuu S, Lawton WA, Palesch Y, Martin RH, AlbersGW, Bath P, Bornstein N, Chan BP, Chen ST, Cunha L, Dahl?f B, De Keyser J, Donnan GA, Estol C, Gorelick P, Gu V, Hermansson K, Hilbrich L, Kaste M, Lu C, Machnig T, Pais P, Roberts R, Skvortsova V, Teal P, Toni D, VanderMaelen C, Voigt T, Weber M, Yoon BW; PRoFESS Study Group. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med, 2008,359(12):1225-1237.
[15] Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, Anderson S, Donovan M, Iverson E, Staiger C, Ptaszynska A; I-PRESERVE Investigators. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med, 2008, 359(23):2456-2467.
[16] Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet, 1999,354(9193):1896-1900.
[17] Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials, 1996,17(1):1-12.
[18] DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials, 1986,7(3):177-188.
[19] Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst, 1959, 22(4):719-748.
[20] Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ, 2003,327(7414):557-560.
[21] Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med, 2002, 21(11):1539-1558.
[22] Sterne JA, Egger M, Smith GD. Systematic reviews in health care: Investigating and dealing with publication and other biases in meta-analysis. BMJ, 2001,323(7304):101-105.
[23] Suzuki H, Kanno Y; Efficacy of Candesartan on Outcome in Saitama Trial (E-COST) Group. Effects of candesartan on cardiovascular outcomes in Japanese hypertensive patients. Hypertens Res, 2005,28(4):307-314.
[24] Mochizuki S, Dahlof B, Shimizu M, Ikewaki K, Yoshikawa M, Taniguchi I, Ohta M, Yamada T, Ogawa K, Kanae K, Kawai M, Seki S, Okazaki F, Taniguchi M, Yoshida S, Tajima N; Jikei Heart Study group. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. Lancet, 2007,369(9571):1431-1439.
[25] Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H; LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet, 2002,359(9311):995-1003.
[26] Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I, Deedwania PC, Ney DE, SnavelyDB, Chang PI. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet, 1997,349(9054):747-752.
[27] Granger CB, Ertl G, Kuch J, Maggioni AP, McMurray J, Rouleau JL, Stevenson LW, Swedberg K, Young J, Yusuf S, Califf RM, Bart BA, Held P, Michelson EL, Sellers MA, Ohlin G, Sparapani R, Pfeffer MA. Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors. Am Heart J, 2000,139(4):609-617.
[28] Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, Konstam MA, Riegger G, Klinger GH, Neaton J, Sharma D, Thiyagarajan B. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II. Lancet, 2000,355(9215):1582-1587.
[29] Dickstein K, Kjekshus J; OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet, 2002,360(9335):752-760.
[30] Berl T, Hunsicker LG, Lewis JB, Pfeffer MA, Porush JG, Rouleau JL, Drury PL, Esmatjes E, Hricik D, Parikh CR, Raz I, Vanhille P, Wiegmann TB, Wolfe BM, Locatelli F, Goldhaber SZ, Lewis EJ; Irbesartan Diabetic Nephropathy Trial. Collaborative Study Group. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med, 2003,138(7):542-549.
[31] Matsumori A; Assessment of Response to Candesartan in Heart Failure in Japan (ARCH-J) Study Investigators. Efficacy and safety of oral candesartan cilexetil in patients with congestive heart failure. Eur J Heart Fail, 2003,5(5):669-677.
[32] Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, Trenkwalder P, Zanchetti A; SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens, 2003,21(5):875-886.
[33] Schrader J, Luders S, Kulschewski A, Berger J, Zidek W, Treib J, Einhaupl K, Diener HC, Dominiak P; Acute Candesartan Cilexetil Therapy in Stroke Survivors Study Group. The ACCESS Study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors. Stroke, 2003,34(7):1699-1703.
[34] McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, Olofsson B, Yusuf S, Pfeffer MA; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet, 2003,362(9386):767-771.
[35] Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, Ostergren J, Pfeffer MA, Swedberg K; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant toangiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet, 2003,362(9386):772-776.
[36] Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet, 2003,362(9386):777-781.
[37] Barnett AH, Bain SC, Bouter P, Karlberg B, Madsbad S, Jervell J, Mustonen J; Diabetics Exposed to Telmisartan and Enalapril Study Group. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med, 2004,351(19):1952-1961.
[38] Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B, Zanchetti A; VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet, 2004,363(9426):2022-2031.
[39] Schrader J, Lu ders S, Kulschewski A, Hammersen F, Plate K, Berger J, Zidek W, Dominiak P, Diener HC; MOSES Study Group. Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES). Stroke, 2005,36(6):1218-1226.
[40] McMurray J, Solomon S, Pieper K, Reed S, Rouleau J, Velazquez E, White H, Howlett J, Swedberg K, Maggioni A, Kober L, Van de Werf F, Califf R, Pfeffer M. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). J Am Coll Cardiol, 2006, 47(4):726-733.
[41] Ogihara T, Nakao K, Fukui T, Fukiyama K, Ueshima K, Oba K, Sato T, Saruta T; Candesartan Antihypertensive Survival Evaluation in Japan Trial Group. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial. Hypertension, 2008,51(2):393-398.
[42] ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med, 2008,358(15):1547-1559.
[43] Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators, Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet, 2008,372(9644):1174-1183.
[44] Anderson CS. The PRoFESS trial results: what went wrong? Int J Stroke, 2008,3(3):165-166.
[45] Lee VC, Rhew DC, Dylan M, Badamgarav E, Braunstein GD, Weingarten SR. Meta-analysis: angiotensin-receptor blockers in chronic heart failure and high-risk acute myocardial infarction.Ann Intern Med, 2004,141(9):693-704.
[46] Turnbull F; Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet, 2003,362(9395):1527-1535.
[47] Reboldi G, Angeli F, Cavallini C, Gentile G, Mancia G, Verdecchia P. Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis. J Hypertens, 2008,26(7):1282-1289.
[48] Sacks HS, Berrier J, Reitman D, Ancona-Berk VA, Chalmers TC. Meta-analyses of randomized controlled trials. N Engl J Med, 1987,316(8):450-455.
[49] Pogue J, Yusuf S. Overcoming the limitations of current meta-analysis of randomised controlled trials. Lancet, 1998,351(9095):47-52.
[50] Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA, 1995,273(5):408-412.
[51] Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, Tugwell P, Klassen TP. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet,1998,352(9128):609-613.
[52] Hopewell S, Loudon K, Clarke MJ, Oxman AD, Dickersin K. Publication bias in clinical trials due to statistical significance or direction of trial results. Cochrane Database Syst Rev, 2009,21(1):MR000006.
[53] The Cochrane Collaboration. Cochrane Handbook for Systematic Reviews of Interventions 4.2.6. Updated September 2006. http://www.cochrane.org/resources/handbook/Handbook 4.2.6 Sep2006.pdf.
[1] Graves BJ, Crowther RL, Chandran C, Rumberger JM, Li S, Huang KS, Presky DH, Familletti PC, Wolitzky BA, Burns DK. Insight into E-selectin/ligand interaction from the crystal structure and mutagenesis of the lec/EGF domains. Nature, 1994, 367(6463):532-538.
[2] Cioffi WG, Burleson DG, Pruitt BA Jr. Leukocyte responses to injury. Arch Surg, 1993, 128(11): 1260-1267.
[3] Chen XL, Tummala PE, Olliff L, Medford RM. E-selectin gene expression in vascular smooth muscle cells, Evidence for a tissue-specific repressor protein. Circ Res, 1997, 80(3):305-311.
[4] Bevilacqua MP, Stengelin S, Gimbrone MA Jr, Seed B. Endothelial leukocyte adhesion molecule 1: an inducible receptor for neutrophils related to complement regulatory proteins and lectins. Science, 1989, 243(4895):1160-1165.
[5]王迎梅,马华,何素兰. E-选择素及基因多态性临床研究进展.海南医学, 2007, 18(6):132-134.
[6] Wenzel K, Felix S, Kleber FX, Brachold R, Menke T, Schattke S, Schulte KL, Gl?ser C, Rohde K, Baumann G. E-selectin polymorphism and atherosclerosis:an association Study. Hum Genet, 1994, 3(11):1935-1937.
[7]姜红,杜明,饶丹. E-选择素基因A128C多态性对冠心病的影响.中国临床医学, 2006, 13(2): 161-163.
[8]胡恒亮,程龙献,苏方成. E-选择素基因S128R多态性与吸烟在冠心病发生中的作用.华中科技大学学报(医学版), 2006, 35(1):115-118.
[9]陈海翎,华琦,刘荣坤,杨峥. E-选择素基因A561C多态性对高血压的影响.中华心血管病杂志, 2005(7), 33: 603-607.
[10] Wu S, Zhou X, Yang H, Yin J, Cai C, Zheng F. Polymorphisms and plasma soluble levels of E-selectin in patients with chronic hepatitis B virus infection. Clin Chem Lab Med, 2009, 47(2):159-164 .
[11] Paterson AD, Lopes-Virella MF, Waggott D, Boright AP, Hosseini SM, Carter RE, Shen E, Mirea L, Bharaj B, Sun L, Bull SB; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Genome-wide association identifies the ABO blood group as a major locus associated with serum levels of soluble E-selectin. Arterioscler Thromb Vasc Biol, 2009, 29(11):1958-1967.
[12] Haidari M, Hajilooi M, Rafiei AR, Rezaii AA, Hoseinipanah SM. E-selectin genetic variation as a susceptibility factor for ischemic stroke. Cerebrovasc Dis, 2009, 28(1):26-32.
[13] Yoshida M, Westlin WF, Wang N, Ingber DE, Rosenzweig A, Resnick N, Gimbrone MA Jr.Leukocyte Adhesion to Vascular Endothelium Induces E-Selectin Linkage to the Actin Cytoskeleton. J Cell Biol, 1996, 133(2):445-455.
[14] Nelson RM, Dolich S, Aruffo A, Cecconi O, Bevilacqua MP. Higher-affinity oligosaccharide ligands for E-selectin. J Clin Invest, 1993, 91(3):1157-1166.
[15] Kiely JM, Hu Y, Garcia-Cardena G, Gimbrone MA Jr. Lipid raft localization of cell surface E-selectin is required for ligation-induced activation of phospholipase C gamma. J Immunol, 2003, 171(6):3216-3224.
[16] Setiadi H, McEver RP. Clustering endothelial E-selectin in clathrin-coated pits and lipid rafts enhances leukocyte adhesion under flow. Blood, 2008, 111(4):1989-1998.
[17] Nauseef WM, Metcalf JA, Root RK, et al . Role of myeloperoxidase in the respiratory burst of human neutrophils. Blood, 1983, 61(3): 483-492.
[18] Chuang PI, Young BA, Thiagarajan RR, Cornejo C, Winn RK, Harlan JM. Cytoplasmic domain of E-selectin contains a non- tyrosine endocytosis signal. J Biol Chem, 1997, 272(40):24813-24818.
[19] Suarez Y, Wang C, Manes TD, Pober JS. Cutting edge: TNF-induced microRNA regulate TNF- induced expression of E-selectin and intercellular adhesion molecule-1 on human endothelial cells: feedback control of inflammation. J Immunol, 2010,184(1):21-25.
[20]朱芸,李明,李世荣.中华风湿病学杂志,2007, 11(1):36-38.
[21]徐建华,徐胜前,张锐等.类风湿关节炎治疗前后可溶性细胞粘附分子-1和E-选择素的变化及其相关性研究.中华风湿病学杂志,2003, 7(10):596-599.
[22] Berger J, Hinglais N. Intercapillairy deposits of IgA-IgG. J Urol Nephrol, 1968, 74(9):694-695.
[23] Takei T, Iida A, Nitta K, Tanaka T, Ohnishi Y, Yamada R, Maeda S, Tsunoda T, Takeoka S, Ito K, Honda K, Uchida K, Tsuchiya K, Suzuki Y, Fujioka T, Ujiie T, Nagane Y, Miyano S, Narita I, Gejyo F, Nihei H, Nakamura Y. Association between single-nucleotide polymorphisms in selectin genes and immunoglobulin A nephropathy. Am J Hum Genet, 2002, 70(3): 781-786.
[24] Matsuo Y, Onodera H, Shiga Y, Nakamura M, Ninomiya M, Kihara T, Kogure K. Correlation between myeloperoxidase-quantified neutrophil accumulation and ischemic brain injury in the rat. Effects of neutrophil depletion. Stroke, 1994, 25(7): 1469-1472.
[25]黄亚波,张世明.选择素对脑缺血再灌注损伤作用的研究进展.中国临床神经科学,2006, 5: 544-548.
[26]吴刚,张世明.人工合成E-选择素对大鼠脑缺血再灌注损伤保护作用的实验研究.中国临床神经科学,2008, 16(2):120-125.
[27]盛文利,李锐,许晓伟. E-选择素介导的大鼠脑缺血再灌注后继发炎症损伤的实验干预.中山大学学报(医学科学版), 2007, 28(1):48-53.
[28] Chen Y, Ruetzler C, Pandipati S, Spatz M, McCarron RM, Becker K, Hallenbeck JM. Mucosal tolerance to E-selectin provides cell-mediated protection against ischemic brain injury. Proc Natl Acad Sci U S A, 2004, 100(25):15107-15112.
[29] Ishibashi S, Maric D, Mou Y, Ohtani R, Ruetzler C, Hallenbeck JM. Mucosal tolerance to E-selectin promotes the survival of newly generated neuroblasts via regulatory T-cell induction after stroke in Spontaneously hypertensive rats . J Cerebral Blood F Met, 2009, 29(3): 606-620.
[30]肖丽红. E-选择素与糖尿病.临床和实验医学杂志,2006, 5(4):419.
[31]牛小燕,朱本章,姚孝礼. E-选择素与糖尿病视网膜病变相关性的研究.中华内分泌代谢杂志,2004, 20(6):538-539.
[32]潘琳,周水平,郭艳茹.黏附分子E-选择素在大鼠糖尿病视网膜病变中的表达.中华眼底病杂志, 2005, 21(5):318-321.
[33] Altannavch TS, RoubalováK, Kucera P, Andel M. Effect of high glucose concentrations on expression of ELAM-1,VCAM-1 and ICAM-1 in HUVEC with and without Cytokine Activation. Physiol Res, 2004, 53(1): 77-82.
[34] Yamaguchi A, Goi T, Yu J, Hirono Y, Ishida M, Iida A, Kimura T, Takeuchi K, Katayama K, Hirose K. Expression of CD44v6 in advanced gastric cancer and its relationship to hematogenous metastasis and long-term prognosis. J Surg Oncol, 2002, 79(4): 230-235.
[35]张勇超.贲门癌患者血清可溶性E-选择素表达及临床意义.山东医药,2009, 49(20):74-75.
[36] Kobayashi K, Matsumoto S, Morishima T, Kawabe T, Okamoto T. Cimetidine Inhibits Cancer Cell Adhesion to Endothelial Cells and Prevents Metastasis by Blocking E-selectin Expression. Cancer Res, 2000, 60(14): 3978-3984.
[37]孙萌,井丽娟. E-选择素与急性肺损伤.国际儿科学杂志,2007, 34(2):93-95.
[38] Abraham E, Carmody A, Shenkar R, Arcaroli J. Neutrophils as early immunologic effectors inhemorrh- age or endotoxemia-induced acute lung injury. Am J Physiol Lung Cell Mol Physiol, 2000, 279(6): L1137-1145.
[39] Abraham E, Kaneko DJ, Shenkar R. Effects of endogenous and exogenous catecholamines on LPS-induced neutrophil trafficking and activation. Am J Physiol Lung Cell Mol Physiol, 1999, 276 (1 Pt 1): L1-8.
[40] Zhou MY, Lo SK, Bergenfeldt M, Tiruppathi C, Jaffe A, Xu N, Malik AB. In Vivo expression of neutrophil inhibitory factor via gene transfer prevents lipopolysaccharide induced lung neutrophil infiltration and injury by a beta2 integrin-dependent mechanism. J Clin Invest, 1998, 101(11):2427-2437.
[41] Harlan JM, Win RK. Leukocyte-endothelial interactions: clinical trials of anti-adhesion therapy.Crit Care Med, 2002, 30 (5 Suppl):S214-219.
[42] Uchiba M, Okajima K, Kaun C, Binder BR, Wojta J. Gabexate mesilate, a synthetic anti-coagulant, inhibits the expression of endothelial leukocyte adhesion molecules in vitro. Crit Care Med, 2003,31(4):1147-1153.
[43]张艰,李圣青,李焕章. NF-κB在大鼠急性肺损伤模型肺组织中的表达及N-乙酰半胱氨酸的影响.细胞与分子免疫杂志,2004, 20(6):712-715.
[44] Schon MP, Krahn T, Schon M, Rodriguez ML, Antonicek H, Schultz JE, Ludwig RJ, Zollner TM, Bischoff E, Bremm KD, Schramm M, Henninger K, Kaufmann R, Gollnick HP, Parker CM, Boehncke WH. Efomycine M, a new specific inhibitor of selectin, impairs leukocyte adhesion and alleviates cutaneous inflammation. Nat Med, 2002,8(4):366-372.
[45] Cockerill GW, Huehns TY, Weerasinghe A, Stocker C, Lerch PG, Miller NE, Haskard DO. Elevation of plasma high-density lipoprotein concentration reduces interleukin-1-induced expression of E-selectin in an in vivo model of acute inflammation. Circulation, 2001, 103(1):108-112.
[46] Slee DH, Romano SJ, Yu J, Nguyen TN, John JK, Raheja NK, Axe FU, Jones TK, Ripka WC. Development of Potent Non-Carbohydrate Imidazole-Based Small Molecule Selectin Inhibitors with Antiinflammatory Activity. J Med Chem, 2001, 41(13): 2094- 2107.
[2] Franco V, Oparil S, Carretero OA. Hypertensive Therapy: PartⅡ. Circulation, 2004, 109(25): 3081-3088.
[3]秦震.我国缺血性脑卒中防治研究中存在的问题及对策.中华医学, 2000,80(2):85-86.
[4] Arboix A, Morcillo C, Garcia-Eroles L, Oliveres M, Massons J, Targa C. Different vascular risk factor profiles in ischemic stroke subtypes: a study from the "Sagrat Cor Hospital of Barcelona Stroke Registry". Acta Neurol Scand, 2000, 102(4):264-270.
[5] Vilas AP, Veiga MZ, Santos ME, Abecasis P. Hemorrhagic stroke: experience of an internal medicine department. Rev Port Cardiol, 2001, 20(2):157-165.
[6] Wolf-Maier K, Cooper RS, Banegas JR, Giampaoli S, Hense HW, Joffres M, Kastarinen M, Poulter N, Primatesta P, Rodríguez-Artalejo F, Stegmayr B, Thamm M, Tuomilehto J, Vanuzzo D, Vescio F. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA, 2003, 289(18):2363-2369.
[7] Lusis AJ. Atherosclerosis. Nature, 2000, 407(6801):233-241.
[8] Libby P, Ridker PM, Maseri A. Inflammation and Atherosclerosis. Circulation, 2002, 105(9):1135-1143.
[9] Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med, 1999, 340(2):115-126.
[10] Mulvihill NT, Foley JB. Inflammation in acute coronary syndroms. Heart, 2002, 87(3):201-204.
[11] Kaartinen M, Penttila A, Kovanen PT. Accumulation of activated mast cells in the shoulder regions of human coronary atheroma, the predilection site of atheromatous rupture. Circulation, 1994, 90(4):1669-1678.
[12] Libby P. Changing concepts of atherogenesis. J Intern Med, 2000, 247(3):349-358.
[13] Bevilacqua MP, Stengelin S, Gimbrone MA Jr, Seed B. Endothelial leukocyte adhesion molecule 1: an inducible receptor for neutrophils related to complement regulatory proteins and lectins. Science, 1989, 243(4895):1160-1165.
[14] Essani NA, McGuire GM, Manning AM, Jaeschke H. Endotoxin-induced actiration of the nuclear transcription factor xB and expression of E-seleetin messenger RNA in hepatocytes, kupfer cells and endothelial cells in vivo. J Immtmol, 1996, 156(8): 2956-2963.
[15] Lawson JA, Burns AR, Farhood A, Lynn Bajt M, Collins RG, Smith CW, Jaeschke H.Pathophysiologie importance of E-and L-selectin for neutrophil-incoeed liver injurv during endotoxe miain mice. Hepatology, 2000, 32(5): 990-998.
[16] Kansas GS. Selectins and their ligands: current concepts and controversies. Blood, l996, 88(9): 3259-3287.
[17] Arenillas JF, Alvarez-Sabín J, Molina CA, Chacón P, Fernández-Cadenas I, Ribo M, Delgado P, Rubiera M, Penalba A, Rovira A, Montaner J. Progression of symptomatic intracranial large artery atherosclerosis is associated with a proinflammatory state and impaired fibrinolysis. Stroke, 2008, 39(5):1456-1463.
[18] Mizia-Stec K, Mandecki T, Zahorska-Markiewicz B, Janowska J, Szulc A, Jastrzebska-OkońK, Twardowski R. P-selectin and E-selectin in serum of patients with stroke. Atherosclerosis, 2002, 161(2): 189-193.
[19] Swanson RA, Morton MT, Tsao-Wu G, Savalos RA, Davidson C, Sharp FR. A semiautomated method for measuring brain infarct volume. J Cereb Blood Flow Metab, 1990, 10(2):290-293.
[20] Zhu W, Fan Y, Frenzel T, Gasmi M, Bartus RT, Young WL, Yang GY, Chen Y. Insulin growth factor-1 gene transfer enhances neurovascular remodeling and improves long-term stroke outcome in mice. Stroke, 2008, 39(4):1254-1261.
[21] Feeney DM, Gonzalez A, Law WA. Amphetamine, haloperidol, and experience interact to affect rate of recovery after motor cortex injury. Science, 1982,217(4562):855-857.
[22] Borlongan CV, Tajima Y, Trojanowski JQ, Lee VM, Sanberg PR. Transplantation of cryopreserved human embryonal carcinoma-derived neurons (NT2N cells) promotes functional recovery ischemic rats. Exp Neurol, 1998,149(2):310-321.
[23] Miao CY, Xie HH, Zhan LS, Su DF. Blood pressure variability is more important than blood pressure level in determination of end-organ damage in rats. J Hypertens, 2006, 24(6):1125-1135.
[24] Liu JG, Xu LP, Chu ZX, Miao CY, Su DF. Contribution of blood pressure variability to the effect of nitrendipine on end-organ damage in spontaneously hypertensive rats. J Hypertens, 2003, 21(10):1961-1967.
[25] Kunkel EJ, Ley K. Distinct phenotype of E-selectin-deficient mice.E-selectin is required for slow leukocyte rolling in vivo. Circ Res, 1996,79(6):1196-1204.
[26] Okamoto K, Yamori Y, Nagaoka A. Establishment of the stroke-prone spontaneously hypertensive rat. Circ Res, 1974,1(2):143-153.
[27] Zeng J, Zhang Y, Mo J, Su Z, Huang R. Two-kidney, two clip renovascular hypertensive rats can be used as stroke-prone rats. Stroke, 1998,29(8):1708-1714.
[28] Becker KJ. Targeting the central nervous system inflammatory response in ischemic stroke. CurtOpin Neurol, 2001;14(3):349-353.
[29] Jean WC, Spellman SR, Nussbaum ES, Low WC. Reperfusion after focal cerebral ischemia: the role of inflammation and the therapeutic horizon. Neurosurgery, 1998,43(6):1382-l396.
[30] Grady MS, Cody RF Jr, Maris DO, McCall TD, Seckin H, Sharar SR, Winn HR. P-selectin blockade following fluid percussion injury: behavioral and immuno-chemical sequelae. J Neurotrauma, 1999, 16(1):13-25.
[31] Clark RS, Schiding JK, Kaczorowski SL, Marion DW, Kochanek PM. Neutrophil accumulation after traumatic brain injury in rats: comparison of weight drop and controlled cortical impact models. J Neurotrauma, 1994,11(5):499-506.
[32] Schoettle RJ, Kochanek PM, Magargee MJ, Uhl MW, Nemoto EM. Early polymorphonuclear leukocyte accumulation correlates with the development of posttraumatic cerebral edema in rats. J Neurotrauma, 1990,7(4):207-217.
[33] Biagas KV, Uhl MW, Schiding JK, Nemoto EM, Kochanek PM. Assessment of posttraumatic polymorphonuclear leukocyte accumulation in rat brain using tissue myeloperoxidase assay and vinblastine treatment. J Neurotrauma, 1992, 9(4):363-371.
[34] Henson PM, Johnston RB Jr. Tissue injury in inflammation: oxidants, proteinases, and cationic proteins. J Clin Invest, 1987,79(3):669-674.
[35] Aly H, Khashaba MT, El-Ayouty M, El-Sayed O, Hasanein BM. IL-1beta, IL-6 and TNF-alpha and outcomes of neonatal hypoxic ischemic encephalopathy. Brain Dev, 2006,28(3):178-182.
[36] Rothwell NJ. Functions and mechanisms of interleukin-1 in the brain. Trends Pharmacol Sci, 1991, 12(11):430-436.
[37] Rothwell NJ, Luheshi G. Pharmacology of intedeukin-1 actions in the brain. Adv Phamaacol, 1994,25(6):1-20.
[38] Stoll G, Jander S, Schroeter M. Inflammation and glia responses in ischemic brain lesions. Prog Neurobiol, 1998,56(2):149-171.
[39] Sharma BK, Kumar K. Role of proinflammatory cytokines in cerebra ischemia. Metab Brain Dis, 1998,13(1):1-8.
[40] Yamasaki Y, Matsuura N, Shozuhara H, Onodera H, Itoyama Y, Kogure K. Interleukin-1 as a pathogenetic mediator of ischemic brain in rats. Stroke, 1995, 26(4): 676-681.
[41] Betz AL, Schiclke GP, Yang GY. Interleukin-1 in cerebral ischemia. Keio J Med, 1996, 45(3):230-238.
[42] Rothwell NJ, Relton JK. Involvement of interleukin-1 and lipocortin-1 in ischemic brain damage. Cerebrovasc Brain Metab Rev, 1993,5(3):178-198.
[43] Kuida K, Lippke JA, Ku G, Harding MW, Livingston DJ, Su MS, Flavell RA. Altered cytokine export and apoptosis in mice deficient in interleukin-1 beta converting enzyme. Science, 1995, 267(5206):2000-2003.
[44] Rothwell NJ. Sixteenth Gaddum Memorial Lecture December 1996. Neuroimmune interactions: the role of cytokines. Br J Pharmacol, 1997, 121(5):841- 847.
[45] Friedlander RM, Yuan J. ICE, neuronal apoptosis and neurodegeneration. Cell Death Diff, 1998, 5(10):823-831.
[1] Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet, 1997,349(9063):1436-1442.
[2] Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet, 2005,365(9455):217-223.
[3] Vongpatanasin W. Cardiovascular morbidity and mortality in high-risk populations: epidemiology and opportunities for risk reduction. J Clin Hypertens, 2007,9(Suppl 4):11-15.
[4] Wang JG, Staessen JA, Franklin SS, Fagard R, Gueyffier F. Systolic and diastolic blood pressure lowering as determinants of cardiovascular outcome. Hypertension, 2005,45(5):907-913.
[5] Elliott WJ. Therapeutic trials comparing angiotensin converting enzyme inhibitors and angiotensin II receptor blockers. Curr Hypertens Rep, 2000,2(4):402-411.
[6] Kleijnen J, Chalmers I. How to practice and teach evidence-based medicine: role of the Cochrane Collaboration. Acta Anaesthesiol Scand Suppl, 1997,111(2):231-233.
[7] Teo KK, Burton JR, Buller CE, Plante S, Catellier D, Tymchak W, Dzavik V, Taylor D, Yokoyama S, Montague TJ. Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: The Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT). Circulation, 2000,102(15):1748-1754.
[8] Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med, 2000,342(3):145-153.
[9] PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet, 2001,358(9287):1033-1041.
[10] Bosch J, Yusuf S, Pogue J, Sleight P, Lonn E, Rangoonwala B, Davies R, Ostergren J, Probstfield J; HOPE Investigators. Heart outcomes prevention evaluation. Use of ramipril in preventing stroke: double blind randomised trial. BMJ, 2002,324(7339):699-702.
[11] Neal B, MacMahon S, Chapman N; Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet, 2000,356(9246):1955-64.
[12] Carr AA, Prisant LM. Losartan: first of a new class of angiotensin antagonists for the management of hypertension. J Clin Pharmacol, 1996,36(1):3-12.
[13] Elliott WJ. Therapeutic trials comparing angiotensin converting enzyme inhibitors and angiotensin II receptor blockers. Curr Hypertens Rep, 2000, 2(4):402-411.
[14] Yusuf S, Diener HC, Sacco RL, Cotton D, Ounpuu S, Lawton WA, Palesch Y, Martin RH, AlbersGW, Bath P, Bornstein N, Chan BP, Chen ST, Cunha L, Dahl?f B, De Keyser J, Donnan GA, Estol C, Gorelick P, Gu V, Hermansson K, Hilbrich L, Kaste M, Lu C, Machnig T, Pais P, Roberts R, Skvortsova V, Teal P, Toni D, VanderMaelen C, Voigt T, Weber M, Yoon BW; PRoFESS Study Group. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med, 2008,359(12):1225-1237.
[15] Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, Anderson S, Donovan M, Iverson E, Staiger C, Ptaszynska A; I-PRESERVE Investigators. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med, 2008, 359(23):2456-2467.
[16] Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet, 1999,354(9193):1896-1900.
[17] Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials, 1996,17(1):1-12.
[18] DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials, 1986,7(3):177-188.
[19] Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst, 1959, 22(4):719-748.
[20] Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ, 2003,327(7414):557-560.
[21] Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med, 2002, 21(11):1539-1558.
[22] Sterne JA, Egger M, Smith GD. Systematic reviews in health care: Investigating and dealing with publication and other biases in meta-analysis. BMJ, 2001,323(7304):101-105.
[23] Suzuki H, Kanno Y; Efficacy of Candesartan on Outcome in Saitama Trial (E-COST) Group. Effects of candesartan on cardiovascular outcomes in Japanese hypertensive patients. Hypertens Res, 2005,28(4):307-314.
[24] Mochizuki S, Dahlof B, Shimizu M, Ikewaki K, Yoshikawa M, Taniguchi I, Ohta M, Yamada T, Ogawa K, Kanae K, Kawai M, Seki S, Okazaki F, Taniguchi M, Yoshida S, Tajima N; Jikei Heart Study group. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. Lancet, 2007,369(9571):1431-1439.
[25] Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H; LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet, 2002,359(9311):995-1003.
[26] Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I, Deedwania PC, Ney DE, SnavelyDB, Chang PI. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet, 1997,349(9054):747-752.
[27] Granger CB, Ertl G, Kuch J, Maggioni AP, McMurray J, Rouleau JL, Stevenson LW, Swedberg K, Young J, Yusuf S, Califf RM, Bart BA, Held P, Michelson EL, Sellers MA, Ohlin G, Sparapani R, Pfeffer MA. Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors. Am Heart J, 2000,139(4):609-617.
[28] Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, Konstam MA, Riegger G, Klinger GH, Neaton J, Sharma D, Thiyagarajan B. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II. Lancet, 2000,355(9215):1582-1587.
[29] Dickstein K, Kjekshus J; OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet, 2002,360(9335):752-760.
[30] Berl T, Hunsicker LG, Lewis JB, Pfeffer MA, Porush JG, Rouleau JL, Drury PL, Esmatjes E, Hricik D, Parikh CR, Raz I, Vanhille P, Wiegmann TB, Wolfe BM, Locatelli F, Goldhaber SZ, Lewis EJ; Irbesartan Diabetic Nephropathy Trial. Collaborative Study Group. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med, 2003,138(7):542-549.
[31] Matsumori A; Assessment of Response to Candesartan in Heart Failure in Japan (ARCH-J) Study Investigators. Efficacy and safety of oral candesartan cilexetil in patients with congestive heart failure. Eur J Heart Fail, 2003,5(5):669-677.
[32] Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, Trenkwalder P, Zanchetti A; SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens, 2003,21(5):875-886.
[33] Schrader J, Luders S, Kulschewski A, Berger J, Zidek W, Treib J, Einhaupl K, Diener HC, Dominiak P; Acute Candesartan Cilexetil Therapy in Stroke Survivors Study Group. The ACCESS Study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors. Stroke, 2003,34(7):1699-1703.
[34] McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, Olofsson B, Yusuf S, Pfeffer MA; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet, 2003,362(9386):767-771.
[35] Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, Ostergren J, Pfeffer MA, Swedberg K; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant toangiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet, 2003,362(9386):772-776.
[36] Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet, 2003,362(9386):777-781.
[37] Barnett AH, Bain SC, Bouter P, Karlberg B, Madsbad S, Jervell J, Mustonen J; Diabetics Exposed to Telmisartan and Enalapril Study Group. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med, 2004,351(19):1952-1961.
[38] Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B, Zanchetti A; VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet, 2004,363(9426):2022-2031.
[39] Schrader J, Lu ders S, Kulschewski A, Hammersen F, Plate K, Berger J, Zidek W, Dominiak P, Diener HC; MOSES Study Group. Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES). Stroke, 2005,36(6):1218-1226.
[40] McMurray J, Solomon S, Pieper K, Reed S, Rouleau J, Velazquez E, White H, Howlett J, Swedberg K, Maggioni A, Kober L, Van de Werf F, Califf R, Pfeffer M. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). J Am Coll Cardiol, 2006, 47(4):726-733.
[41] Ogihara T, Nakao K, Fukui T, Fukiyama K, Ueshima K, Oba K, Sato T, Saruta T; Candesartan Antihypertensive Survival Evaluation in Japan Trial Group. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial. Hypertension, 2008,51(2):393-398.
[42] ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med, 2008,358(15):1547-1559.
[43] Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators, Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet, 2008,372(9644):1174-1183.
[44] Anderson CS. The PRoFESS trial results: what went wrong? Int J Stroke, 2008,3(3):165-166.
[45] Lee VC, Rhew DC, Dylan M, Badamgarav E, Braunstein GD, Weingarten SR. Meta-analysis: angiotensin-receptor blockers in chronic heart failure and high-risk acute myocardial infarction.Ann Intern Med, 2004,141(9):693-704.
[46] Turnbull F; Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet, 2003,362(9395):1527-1535.
[47] Reboldi G, Angeli F, Cavallini C, Gentile G, Mancia G, Verdecchia P. Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis. J Hypertens, 2008,26(7):1282-1289.
[48] Sacks HS, Berrier J, Reitman D, Ancona-Berk VA, Chalmers TC. Meta-analyses of randomized controlled trials. N Engl J Med, 1987,316(8):450-455.
[49] Pogue J, Yusuf S. Overcoming the limitations of current meta-analysis of randomised controlled trials. Lancet, 1998,351(9095):47-52.
[50] Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA, 1995,273(5):408-412.
[51] Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, Tugwell P, Klassen TP. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet,1998,352(9128):609-613.
[52] Hopewell S, Loudon K, Clarke MJ, Oxman AD, Dickersin K. Publication bias in clinical trials due to statistical significance or direction of trial results. Cochrane Database Syst Rev, 2009,21(1):MR000006.
[53] The Cochrane Collaboration. Cochrane Handbook for Systematic Reviews of Interventions 4.2.6. Updated September 2006. http://www.cochrane.org/resources/handbook/Handbook 4.2.6 Sep2006.pdf.
[1] Graves BJ, Crowther RL, Chandran C, Rumberger JM, Li S, Huang KS, Presky DH, Familletti PC, Wolitzky BA, Burns DK. Insight into E-selectin/ligand interaction from the crystal structure and mutagenesis of the lec/EGF domains. Nature, 1994, 367(6463):532-538.
[2] Cioffi WG, Burleson DG, Pruitt BA Jr. Leukocyte responses to injury. Arch Surg, 1993, 128(11): 1260-1267.
[3] Chen XL, Tummala PE, Olliff L, Medford RM. E-selectin gene expression in vascular smooth muscle cells, Evidence for a tissue-specific repressor protein. Circ Res, 1997, 80(3):305-311.
[4] Bevilacqua MP, Stengelin S, Gimbrone MA Jr, Seed B. Endothelial leukocyte adhesion molecule 1: an inducible receptor for neutrophils related to complement regulatory proteins and lectins. Science, 1989, 243(4895):1160-1165.
[5]王迎梅,马华,何素兰. E-选择素及基因多态性临床研究进展.海南医学, 2007, 18(6):132-134.
[6] Wenzel K, Felix S, Kleber FX, Brachold R, Menke T, Schattke S, Schulte KL, Gl?ser C, Rohde K, Baumann G. E-selectin polymorphism and atherosclerosis:an association Study. Hum Genet, 1994, 3(11):1935-1937.
[7]姜红,杜明,饶丹. E-选择素基因A128C多态性对冠心病的影响.中国临床医学, 2006, 13(2): 161-163.
[8]胡恒亮,程龙献,苏方成. E-选择素基因S128R多态性与吸烟在冠心病发生中的作用.华中科技大学学报(医学版), 2006, 35(1):115-118.
[9]陈海翎,华琦,刘荣坤,杨峥. E-选择素基因A561C多态性对高血压的影响.中华心血管病杂志, 2005(7), 33: 603-607.
[10] Wu S, Zhou X, Yang H, Yin J, Cai C, Zheng F. Polymorphisms and plasma soluble levels of E-selectin in patients with chronic hepatitis B virus infection. Clin Chem Lab Med, 2009, 47(2):159-164 .
[11] Paterson AD, Lopes-Virella MF, Waggott D, Boright AP, Hosseini SM, Carter RE, Shen E, Mirea L, Bharaj B, Sun L, Bull SB; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Genome-wide association identifies the ABO blood group as a major locus associated with serum levels of soluble E-selectin. Arterioscler Thromb Vasc Biol, 2009, 29(11):1958-1967.
[12] Haidari M, Hajilooi M, Rafiei AR, Rezaii AA, Hoseinipanah SM. E-selectin genetic variation as a susceptibility factor for ischemic stroke. Cerebrovasc Dis, 2009, 28(1):26-32.
[13] Yoshida M, Westlin WF, Wang N, Ingber DE, Rosenzweig A, Resnick N, Gimbrone MA Jr.Leukocyte Adhesion to Vascular Endothelium Induces E-Selectin Linkage to the Actin Cytoskeleton. J Cell Biol, 1996, 133(2):445-455.
[14] Nelson RM, Dolich S, Aruffo A, Cecconi O, Bevilacqua MP. Higher-affinity oligosaccharide ligands for E-selectin. J Clin Invest, 1993, 91(3):1157-1166.
[15] Kiely JM, Hu Y, Garcia-Cardena G, Gimbrone MA Jr. Lipid raft localization of cell surface E-selectin is required for ligation-induced activation of phospholipase C gamma. J Immunol, 2003, 171(6):3216-3224.
[16] Setiadi H, McEver RP. Clustering endothelial E-selectin in clathrin-coated pits and lipid rafts enhances leukocyte adhesion under flow. Blood, 2008, 111(4):1989-1998.
[17] Nauseef WM, Metcalf JA, Root RK, et al . Role of myeloperoxidase in the respiratory burst of human neutrophils. Blood, 1983, 61(3): 483-492.
[18] Chuang PI, Young BA, Thiagarajan RR, Cornejo C, Winn RK, Harlan JM. Cytoplasmic domain of E-selectin contains a non- tyrosine endocytosis signal. J Biol Chem, 1997, 272(40):24813-24818.
[19] Suarez Y, Wang C, Manes TD, Pober JS. Cutting edge: TNF-induced microRNA regulate TNF- induced expression of E-selectin and intercellular adhesion molecule-1 on human endothelial cells: feedback control of inflammation. J Immunol, 2010,184(1):21-25.
[20]朱芸,李明,李世荣.中华风湿病学杂志,2007, 11(1):36-38.
[21]徐建华,徐胜前,张锐等.类风湿关节炎治疗前后可溶性细胞粘附分子-1和E-选择素的变化及其相关性研究.中华风湿病学杂志,2003, 7(10):596-599.
[22] Berger J, Hinglais N. Intercapillairy deposits of IgA-IgG. J Urol Nephrol, 1968, 74(9):694-695.
[23] Takei T, Iida A, Nitta K, Tanaka T, Ohnishi Y, Yamada R, Maeda S, Tsunoda T, Takeoka S, Ito K, Honda K, Uchida K, Tsuchiya K, Suzuki Y, Fujioka T, Ujiie T, Nagane Y, Miyano S, Narita I, Gejyo F, Nihei H, Nakamura Y. Association between single-nucleotide polymorphisms in selectin genes and immunoglobulin A nephropathy. Am J Hum Genet, 2002, 70(3): 781-786.
[24] Matsuo Y, Onodera H, Shiga Y, Nakamura M, Ninomiya M, Kihara T, Kogure K. Correlation between myeloperoxidase-quantified neutrophil accumulation and ischemic brain injury in the rat. Effects of neutrophil depletion. Stroke, 1994, 25(7): 1469-1472.
[25]黄亚波,张世明.选择素对脑缺血再灌注损伤作用的研究进展.中国临床神经科学,2006, 5: 544-548.
[26]吴刚,张世明.人工合成E-选择素对大鼠脑缺血再灌注损伤保护作用的实验研究.中国临床神经科学,2008, 16(2):120-125.
[27]盛文利,李锐,许晓伟. E-选择素介导的大鼠脑缺血再灌注后继发炎症损伤的实验干预.中山大学学报(医学科学版), 2007, 28(1):48-53.
[28] Chen Y, Ruetzler C, Pandipati S, Spatz M, McCarron RM, Becker K, Hallenbeck JM. Mucosal tolerance to E-selectin provides cell-mediated protection against ischemic brain injury. Proc Natl Acad Sci U S A, 2004, 100(25):15107-15112.
[29] Ishibashi S, Maric D, Mou Y, Ohtani R, Ruetzler C, Hallenbeck JM. Mucosal tolerance to E-selectin promotes the survival of newly generated neuroblasts via regulatory T-cell induction after stroke in Spontaneously hypertensive rats . J Cerebral Blood F Met, 2009, 29(3): 606-620.
[30]肖丽红. E-选择素与糖尿病.临床和实验医学杂志,2006, 5(4):419.
[31]牛小燕,朱本章,姚孝礼. E-选择素与糖尿病视网膜病变相关性的研究.中华内分泌代谢杂志,2004, 20(6):538-539.
[32]潘琳,周水平,郭艳茹.黏附分子E-选择素在大鼠糖尿病视网膜病变中的表达.中华眼底病杂志, 2005, 21(5):318-321.
[33] Altannavch TS, RoubalováK, Kucera P, Andel M. Effect of high glucose concentrations on expression of ELAM-1,VCAM-1 and ICAM-1 in HUVEC with and without Cytokine Activation. Physiol Res, 2004, 53(1): 77-82.
[34] Yamaguchi A, Goi T, Yu J, Hirono Y, Ishida M, Iida A, Kimura T, Takeuchi K, Katayama K, Hirose K. Expression of CD44v6 in advanced gastric cancer and its relationship to hematogenous metastasis and long-term prognosis. J Surg Oncol, 2002, 79(4): 230-235.
[35]张勇超.贲门癌患者血清可溶性E-选择素表达及临床意义.山东医药,2009, 49(20):74-75.
[36] Kobayashi K, Matsumoto S, Morishima T, Kawabe T, Okamoto T. Cimetidine Inhibits Cancer Cell Adhesion to Endothelial Cells and Prevents Metastasis by Blocking E-selectin Expression. Cancer Res, 2000, 60(14): 3978-3984.
[37]孙萌,井丽娟. E-选择素与急性肺损伤.国际儿科学杂志,2007, 34(2):93-95.
[38] Abraham E, Carmody A, Shenkar R, Arcaroli J. Neutrophils as early immunologic effectors inhemorrh- age or endotoxemia-induced acute lung injury. Am J Physiol Lung Cell Mol Physiol, 2000, 279(6): L1137-1145.
[39] Abraham E, Kaneko DJ, Shenkar R. Effects of endogenous and exogenous catecholamines on LPS-induced neutrophil trafficking and activation. Am J Physiol Lung Cell Mol Physiol, 1999, 276 (1 Pt 1): L1-8.
[40] Zhou MY, Lo SK, Bergenfeldt M, Tiruppathi C, Jaffe A, Xu N, Malik AB. In Vivo expression of neutrophil inhibitory factor via gene transfer prevents lipopolysaccharide induced lung neutrophil infiltration and injury by a beta2 integrin-dependent mechanism. J Clin Invest, 1998, 101(11):2427-2437.
[41] Harlan JM, Win RK. Leukocyte-endothelial interactions: clinical trials of anti-adhesion therapy.Crit Care Med, 2002, 30 (5 Suppl):S214-219.
[42] Uchiba M, Okajima K, Kaun C, Binder BR, Wojta J. Gabexate mesilate, a synthetic anti-coagulant, inhibits the expression of endothelial leukocyte adhesion molecules in vitro. Crit Care Med, 2003,31(4):1147-1153.
[43]张艰,李圣青,李焕章. NF-κB在大鼠急性肺损伤模型肺组织中的表达及N-乙酰半胱氨酸的影响.细胞与分子免疫杂志,2004, 20(6):712-715.
[44] Schon MP, Krahn T, Schon M, Rodriguez ML, Antonicek H, Schultz JE, Ludwig RJ, Zollner TM, Bischoff E, Bremm KD, Schramm M, Henninger K, Kaufmann R, Gollnick HP, Parker CM, Boehncke WH. Efomycine M, a new specific inhibitor of selectin, impairs leukocyte adhesion and alleviates cutaneous inflammation. Nat Med, 2002,8(4):366-372.
[45] Cockerill GW, Huehns TY, Weerasinghe A, Stocker C, Lerch PG, Miller NE, Haskard DO. Elevation of plasma high-density lipoprotein concentration reduces interleukin-1-induced expression of E-selectin in an in vivo model of acute inflammation. Circulation, 2001, 103(1):108-112.
[46] Slee DH, Romano SJ, Yu J, Nguyen TN, John JK, Raheja NK, Axe FU, Jones TK, Ripka WC. Development of Potent Non-Carbohydrate Imidazole-Based Small Molecule Selectin Inhibitors with Antiinflammatory Activity. J Med Chem, 2001, 41(13): 2094- 2107.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |